CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $4.21M rose 10.3% year over year, behind the +13.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.8% from the prior quarter.
Context
- Selling, general & admin amounted to 496.2% of revenue in FY2025, down 1792.6 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $133.78M (+670.7%) for the fiscal year ending Dec 2026, a step up from the +16.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.21M-11.8% QoQ
- Last fiscal yearDec 2025
- $17.36M+16.3% YoY
- LTMMar 2026
- $17.75M+13.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 17.36M USD
- Year-over-year change
- +16.3%
- 4-year CAGR
- -35.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.36M | +16.3% |
| FY2024 | 2024-12-31 | 14.92M | +28.5% |
| FY2023 | 2023-11-30 | 11.61M | +13.5% |
| FY2022 | 2023-02-28 | 10.23M | -89.9% |
| FY2021 | 2022-02-28 | 100.9M | — |
Selling, General & Admin vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.9% is the 3rd highest of 9, against a peer median of -9.1%.
- Selling, general & admin amounts to 451.2% of revenue for CAMP, versus a peer median of 100.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M USD | -10.5% | +40.4% | — |
| LTM Mar 2026 | $21.4M USD | +37.8% | +45.9% | — | |
| LTM Mar 2026 | $21.28M USD | -23.4% | -6.3% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$18.43M CAD | +3.9% | +1.8% | 100.4% |
| LTM Mar 2026 | $17.76M USD | +24.8% | +12.7% | 9346.3% | |
| LTM Mar 2026 | $17.75M USD | +13.9% | — | 451.2% | |
| LTM Mar 2026 | $17.18M USD | -7.7% | -15.7% | 6.7% | |
| LTM Mar 2026 | $16.17M USD | -36.6% | -2.6% | — | |
| LTM Mar 2026 | $15.9M USD | -38.9% | -12.9% | — | |
| Peer median (excluding CAMP) | — | -9.1% | -0.4% | 100.4% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Nov 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.84M | 0 | 350K | 652K | 3.5M |
| Cost of Revenue | 173.95M | 0 | 0 | 0 | 1.64M |
| Gross Profit | 121.89M | (947K) | 350K | 652K | 1.86M |
| Gross Margin | 41.2% | — | 100.0% | 100.0% | 53.1% |
| Research & Development | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M |
| Selling, General & Admin | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M |
| Operating Expenses | 134.76M | 45M | 52.23M | 53.74M | 53.92M |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| EBITDA | 7.49M | (44.12M) | (50.2M) | (51.39M) | (50.42M) |
| EBITDA Margin | 2.5% | — | -14343.1% | -7882.2% | -1441.5% |
| Operating Income | (15.31M) | (45M) | (51.88M) | (53.09M) | (52.06M) |
| Operating Margin | -5.2% | — | -14822.6% | -8142.3% | -1488.3% |
| Interest Income | 0 | 0 | 2.81M | 1.33M | 2.17M |
| Interest Expense | 15.32M | 6.26M | 0 | 0 | 0 |
| Other Income / Expenses | (14.75M) | 809K | 2.59M | 1.3M | (28.34M) |
| Income Before Tax | (30.06M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Pre-Tax Margin | -10.2% | — | -14083.1% | -7943.4% | -2298.5% |
| Income Tax Expense | 1.09M | 0 | 0 | 0 | 0 |
| Net Income | (31.15M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Net Margin | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (Basic) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| EPS (Diluted) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| Weighted Avg Shares | 35.25M | 36.1M | 12.12M | 19.51M | 30.38M |
| Weighted Avg Shares (Diluted) | 35.25M | 36.13M | 12.12M | 19.51M | 30.38M |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.